EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of microRNAs in Chronic Lymphocytic Leukemia

Francesco Autore, Alice Ramassone, Luca Stirparo, Sara Pagotto iD, Alberto Fresa iD, Idanna Innocenti, Rosa Visone, Luca Laurenti iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241512471 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Francesco Autore und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, I…. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, AIRC fellowship for Italy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, with a highly variable clinical course. Improvement in the knowledge of the molecular pathways behind this disease has led to the development of increasingly specific therapies, such as BCR signaling inhibitors and BCL-2 inhibitors. In this context, the emerging role of microRNAs (miRNAs) in CLL pathophysiology and their possible application in therapy is worth noting. MiRNAs are one of the most important regulatory molecules of gene expression. In CLL, they can act both as oncogenes and tumor suppressor genes, and the deregulation of specific miRNAs has been associated with prognosis, progression, and drug resistance. In this review, we describe the role of the miRNAs that primarily impact the disease, and how these miRNAs could be used as therapeutic tools. Certainly, the use of miRNAs in clinical practice is still limited in CLL. Many issues still need to be solved, particularly regarding their biological and safety profile, even if several studies have suggested their efficacy on the disease, alone or in combination with other drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHumansOncogenesSignal Transduction

Stichwörter der Autor:innen

CLLmicroRNAtherapy

Substanzen

MicroRNAsAntineoplastic Agents

Autor:innen und Institutionen

  • Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy.
  • Center for Advanced Studies and Technology (CAST), G. d'Annunzio University, 66100 Chieti, Italy.
  • Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University, 66100 Chieti, Italy.
  • Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.

ORCID-Profile: Sara Pagotto, Alberto Fresa, Luca Laurenti

Förderung

  • Italian Association for Cancer Research
  • AIRC fellowship for Italy

Zitieren

APA

Autore, F., Ramassone, A., Stirparo, L., Pagotto, S., Fresa, A., Innocenti, I., Visone, R., & Laurenti, L. (2023). Role of microRNAs in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512471

Vancouver

Autore F, Ramassone A, Stirparo L, Pagotto S, Fresa A, Innocenti I, et al. Role of microRNAs in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512471

BibTeX
@article{Autore2023,
  author = {Autore, Francesco and Ramassone, Alice and Stirparo, Luca and Pagotto, Sara and Fresa, Alberto and Innocenti, Idanna and Visone, Rosa and Laurenti, Luca},
  title = {Role of microRNAs in Chronic Lymphocytic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512471}
}
Kostenlos starten →